Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment

被引:134
作者
Semb, KA [1 ]
Aamdal, S
Oian, P
机构
[1] Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway
[2] Univ Tromso, Dept Obstet & Gynecol, Tromso, Norway
关键词
D O I
10.1200/JCO.1998.16.10.3426
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of our study was to elucidate whether the fluid retention syndrome induced by docetaxel is caused by capillary protein leakage or by other mechanisms. Patients and Methods: Twenty-four patients with advanced or metastatic non-small-cell lung cancer (NSCLC; 23 patients) or metastatic head and neck cancer (one patient) were included on this prospective, nonrandomized trial. Docetaxel 100 mg/m(2) was administered every 3 weeks with 5 days of dexamethasone prophylaxis to avoid hypersensitivity reactions and edema formation. Transcapillary forces, ie, colloid osmotic pressure of plasma (COPpl) and interstitial fluid (COPint) and interstitial hydrostatic pressure (P-int), were measured before the start of treatment and after total docetaxel doses of 200 and 500 mg/m(2) by means of the well-documented wick and wick-in-needle methods. Body weight, degree of edema, blood pressure, and heart rare and hemoglobin, hematocrit, albumin, and total protein values were registered in parallel. Results: After a total docetaxel dose of 200 mg/m(2), COPpl, COPint, and hemoglobin, hematocrit, albumin, and total protein values had decreased significantly; P-int and body weight were unchanged; and only mild edema was observed. These findings suggest a plasma volume increase followed by enhanced fluid filtration to the interstitium. After a cumulative docetaxel dose of 500 mg/m(2), the COPpl continued to decrease significantly, but COPint remained unchanged despite a significant increase in mean body weight and edema formation. These observations support the theory of a capillary protein leakage. Conclusion: Docetaxel appears to induce an initial enhancement of fluid filtration followed by a capillary protein leakage that leads to edema formation. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:3426 / 3432
页数:7
相关论文
共 36 条
[1]   DOCETAXEL (TAXOTERE) IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP [J].
AAMDAL, S ;
WOLFF, I ;
KAPLAN, S ;
PARIDAENS, R ;
KERGER, J ;
SCHACHTER, J ;
WANDERS, J ;
FRANKLIN, HR ;
VERWEIJ, J .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) :1061-1064
[2]  
AISSA DO, 1994, P AN M AM SOC CLIN, V13, P465
[3]   INTERSTITIAL-LYMPHATIC MECHANISMS IN THE CONTROL OF EXTRACELLULAR FLUID VOLUME [J].
AUKLAND, K ;
REED, RK .
PHYSIOLOGICAL REVIEWS, 1993, 73 (01) :1-78
[4]   COLLOID OSMOMETER FOR SMALL FLUID SAMPLES [J].
AUKLAND, K ;
JOHNSEN, HM .
ACTA PHYSIOLOGICA SCANDINAVICA, 1974, 90 (02) :485-490
[5]   The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication [J].
Behar, A ;
PujadeLauraine, E ;
Maurel, A ;
Brun, MD ;
Lagrue, G ;
DeChauvin, FF ;
OulidAissa, D ;
Hille, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) :653-658
[6]  
BISSERY MC, 1991, CANCER RES, V51, P4845
[7]   DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER [J].
CHEVALLIER, B ;
FUMOLEAU, P ;
KERBRAT, P ;
DIERAS, V ;
ROCHE, H ;
KRAKOWSKI, I ;
AZLI, N ;
BAYSSAS, M ;
LENTZ, MA ;
VANGLABBEKE, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :314-322
[8]  
Fadnes H O, 1989, Obstet Gynecol Surv, V44, P769
[9]   INTERSTITIAL FLUID PRESSURE IN RATS MEASURED WITH A MODIFIED WICK TECHNIQUE [J].
FADNES, HO ;
REED, RK ;
AUKLAND, K .
MICROVASCULAR RESEARCH, 1977, 14 (01) :27-36
[10]   INTERSTITIAL FLUID VOLUME, PLASMA-VOLUME AND COLLOID OSMOTIC-PRESSURE IN PATIENTS WITH NEPHROTIC SYNDROME [J].
FAUCHALD, P ;
NODDELAND, H ;
NORSETH, J .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1984, 44 (07) :661-667